Pluristyx, panCELLa, and Implant Therapeutics Announce a Strategic Alliance to Manufacture and Distribute Genetically Modified, Clinical-grade Human-induced Pluripotent Stem Cells January 20, 2022 by Businesswire [#item_full_content] Related Spread the word